X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Merck reported that, based on the additional research that would be required – new clinical trials as well as research related to manufacturing at scale – MK-7110 would not be expected to become available until the first half of 2022.
Lead Product(s): MK-7110
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-7110
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
Merck has reported that U.S. regulators have asked for additional data beyond the Phase III study already conducted in order to support potential emergency use authorization of its experimental COVID-19 drug MK-7110.
Lead Product(s): MK-7110
Therapeutic Area: Infections and Infectious Diseases Product Name: CD24Fc
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
Under the agreement, Merck will receive up to approximately $356 million for manufacturing and supply of approximately 60,000-100,000 doses of MK-7110 to the U.S. Government through June 30, 2021 to meet the government’s Operation Warp Speed goals.
Lead Product(s): MK-7110
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-7110
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Government
Deal Size: $356.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 23, 2020
Details:
Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19. Merck will accelerate development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19.
Lead Product(s): MK-7110
Therapeutic Area: Infections and Infectious Diseases Product Name: CD24Fc
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $425.0 million Upfront Cash: $425.0 million
Deal Type: Acquisition November 23, 2020
Details:
Data from 203 participants show that severe or critical COVID-19 patients treated with SACCOVID exhibited significantly faster recovery and significantly reduced disease progression to death or respiratory failure than those receiving placebo.
Lead Product(s): MK-7110
Therapeutic Area: Infections and Infectious Diseases Product Name: Saccovid
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
Oncoimmune will use the proceeds to support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline. OncoImmune currently has two Phase III clinical programs to evaluate its lead product CD24Fc.
Lead Product(s): MK-7110
Therapeutic Area: Infections and Infectious Diseases Product Name: CD24Fc
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: HM Capital
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 09, 2020
Details:
The first 70 patients have been randomized and received either CD24Fc or placebo as the treatment for severe COVID-19.
Lead Product(s): MK-7110
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2020
Details:
The new trial will test the impact of OncoImmune’s flagship product, CD24Fc, in dampening inflammation caused by virus-induced cellar injuries, in severe COVID-19 patients.
Lead Product(s): MK-7110
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Details:
The trial is intended for use in HIV patients who have been receiving the traditional antiretroviral therapies that control, but do not cure, HIV infection.
Lead Product(s): MK-7110
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2020
Details:
The study, compares safety and efficacy data of CD24Fc when used in combination with standard of care GVHD prophylaxis compared to placebo and historical controls.
Lead Product(s): MK-7110,Methotrexate,Tacrolimus
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
